These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24570296)

  • 1. Theoretical consideration of the effect of drug holidays on BMD and tissue age.
    Hernandez CJ; Lopez HK; Lane JM
    Osteoporos Int; 2014 May; 25(5):1577-84. PubMed ID: 24570296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
    Nayak S; Greenspan SL
    Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of anti-resorptive agents on trabecular bone score (TBS) in older women.
    Krieg MA; Aubry-Rozier B; Hans D; Leslie WD;
    Osteoporos Int; 2013 Mar; 24(3):1073-8. PubMed ID: 23052939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
    Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
    Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
    Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic setting.
    Roberts J; Castro C; Moore AE; Fogelman I; Hampson G
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):509-15. PubMed ID: 26715263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
    Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
    Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis.
    Nakamura T; Ito M; Hashimoto J; Shinomiya K; Asao Y; Katsumata K; Hagino H; Inoue T; Nakano T; Mizunuma H;
    Osteoporos Int; 2015 Nov; 26(11):2685-93. PubMed ID: 26001561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis--a double-blind, randomized, dose-finding study.
    Nakamura T; Shiraki M; Fukunaga M; Tomomitsu T; Santora AC; Tsai R; Fujimoto G; Nakagomi M; Tsubouchi H; Rosenberg E; Uchida S
    Osteoporos Int; 2014 Jan; 25(1):367-76. PubMed ID: 23716037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting.
    Chiha M; Myers LE; Ball CA; Sinacore JM; Camacho PM
    Endocr Pract; 2013; 19(6):989-94. PubMed ID: 24013976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density in osteoporotic patients with pyogenic vertebral osteomyelitis: effect of early versus late treatment for osteoporosis.
    Kim J; Kim SW; Lee SY; Kim TH; Jung JH
    Osteoporos Int; 2018 Dec; 29(12):2761-2770. PubMed ID: 30225674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of bone remodeling agents following teriparatide treatment.
    Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
    Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retained Skeletal Effects of Zoledronic Acid Following Discontinuation of Treatment: A Review of the Literature.
    Deas CM; Murphy P; Iranikhah M; Freeman MK
    Consult Pharm; 2017 Mar; 32(3):144-155. PubMed ID: 28270269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
    Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
    Cairoli E; Eller-Vainicher C; Ulivieri FM; Zhukouskaya VV; Palmieri S; Morelli V; Beck-Peccoz P; Chiodini I
    Osteoporos Int; 2014 Apr; 25(4):1401-10. PubMed ID: 24510095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.